High frequency of CYP2C19*2 carriers in PCI-treated patients switched over from clopidogrel to prasugrel based on platelet function monitoring.
Isabell
I
Bernlochner
Katharina
K
Mayer
Tanja
T
Morath
Siegmund
S
Braun
Stefanie
S
Schulz
Albert
A
Schömig
Werner
W
Koch
Adnan
A
Kastrati
Dirk
D
Sibbing
D001189:Aryl Hydrocarbon Hydroxylases / Q000235:genetics*; D000077144:Clopidogrel; D065731:Cytochrome P-450 CYP2C19; D057915:Drug Substitution; D006579:Heterozygote; D006801:Humans; D062645:Percutaneous Coronary Intervention / Q000009:adverse effects; D010879:Piperazines / Q000008:administration & dosage*; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage*; D000068799:Prasugrel Hydrochloride; D013876:Thiophenes / Q000008:administration & dosage*; D013927:Thrombosis / Q000235:genetics / Q000517:prevention & control; D013988:Ticlopidine / Q000008:administration & dosage / Q000031:analogs & derivatives*
D010879:Piperazines; D010975:Platelet Aggregation Inhibitors; D013876:Thiophenes; D000077144:Clopidogrel; D001189:Aryl Hydrocarbon Hydroxylases; C045793:CYP2C19 protein, human; D065731:Cytochrome P-450 CYP2C19; D000068799:Prasugrel Hydrochloride; D013988:Ticlopidine